2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
Investors seeking growth opportunities in 2025's volatile market are turning to healthcare stocks with proven momentum. Hims & Hers Health (HIMS) exemplifies this trend, delivering a staggering 200% return over the past year—outpacing the broader market's 18% gain. The company's innovative approach to affordable weight-loss medications, including compounded GLP-1 drugs, fueled its meteoric rise.
Regulatory headwinds emerged when the FDA restricted mass production of compounded semaglutide, creating new challenges for the telehealth provider. Yet market analysts remain bullish on the stock's long-term potential, citing the company's adaptable business model and expanding digital health services.